Hepatitis C Virus Genotyping versus Serotyping in Egyptian Patients

Zekri, Abdel‐Rahman N.; Bahnassy, Abeer A.; Ramadan, A. M.; El-Bassuoni, Maha A.; Badran, Aya Y.; Madwar, M. A.

doi:10.1007/s15010-001-0010-8

Cited by 24 publications

(17 citation statements)

References 9 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, this performance was consistent with those described elsewhere (2,12,15,39). The genotyping assay failed for three samples, which were later identified as type 2 by the serological method.…”

Section: Discussionsupporting

confidence: 89%

“…The sensitivity of the serological typing assay was 70% in relation to the results obtained by the genotyping assay. This rate, which is lower than those previously reported (23,37,39), could be explained by the high prevalence of genotype 5 in the population studied. Gault et al recently reported that a kit from the same manufacturer using a new version of the HCV serotyping 1-6 assay gave better results for rare types (11).…”

Section: Discussioncontrasting

confidence: 88%

“…While the presence of cross-reactivities cannot be excluded as a cause of mistyping by the serological assay, it is generally admitted that serological methods are more sensitive for detecting mixed or sequential infections (29,30,39). Molecular biology-based methods are less effective for identifying mixed infections because one strain is often predominant and is the only one amplified by PCR.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002

et al. 2004

View full text Add to dashboard Cite

From 1996 to 2002, hepatitis C virus (HCV) typing was prospectively performed for 1,281 unselected HCV-infected and viremic patients, irrespective of their clinical status. Eighty-three patients (6.5%) were coinfected with human immunodeficiency virus (HIV) and HCV. A total of 1,195 strains were identified by a serotype screening (Murex HCV Serotyping 1-6 assay) and/or genotyping (Inno-LiPA HCV II) test. The distribution of HCV types showed an unusually high rate of type 5 (14.2%) that was stable over time and was the third most frequent type, after type 1 (59.1%) and type 3 (15.1%). HCV type 5 was more frequent in patients who were older than 50 (P ‫؍‬ 10 ؊6 ), but its frequency did not differ significantly by gender (P ‫؍‬ 0.21). Serotyping was performed for 1,160 strains but failed for 30.2% of them. The efficiency depended on HIV status (for HCV-HIV-coinfected patients, half of the strains were untypeable) and HCV type. Genotyping was performed for 428 samples, with an overall efficiency of 99.3%. It failed in three cases, which were subsequently identified as HCV type 2. Serotyping and genotyping results for 39 patients showed discrepancies between the two methods for 4 patients, who had HCV type 2, type 6, or mixed infections. Thus, HCV type 5 may also be encountered frequently in Western countries. Its apparent confinement to a restricted area raises the question of how it emerged and underscores the need for further studies of HCV type prevalence, routes of transmission, pathogenicity, and responses to treatment.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussioncontrasting

confidence: 88%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002

et al. 2004

View full text Add to dashboard Cite

show abstract

“…This disagreement was reported by others [Chen and Weck, 2002;Nolte et al, 2003]. The lack of agreement reported in this study at the subtype level is not surprising considering the high diversity of genotype 4, especially in the Egyptian population as previously shown by others [Zekri et al, 2001] comparing sero-and geno-typing methods, The detection of a large number of individual mutated strains by hybridization assay such as INNO-LiPA in a single test is difficult since it requires very high stringent conditions [Ansaldi et al, 2001]. Also the lack of agreement between the subtypes is not unusual considering that both methods target the 5 0 NC region.…”

Section: Discussioncontrasting

confidence: 66%

TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4

et al. 2005

View full text Add to dashboard Cite

Hepatitis C virus genotypes and subtypes determination is an important factor for understanding the epidemiology of the virus, in the pre-treatment evaluation of the patients and in defining better treatment strategies. In the present study, we compared two commercially available assays for HCV genotyping: the reverse hybridization based Innogenetics INNO-LiPA HCV II and the direct sequencing by TRUGENE assay. The study included 31 HCV-RNA positive Egyptian patients; 18 patients with chronic active hepatitis, 8 with HCC, and 5 with cirrhosis. Using the TRUGENE genotyping test, all the samples had genotype 4 (100%) and subtyped as 4a in 18/31(58%), 4c in 10/31 (32%), 4e in 1/31 (3%), 4a/c in 1/31 (3%), and 4g in 1/31 (3%). Using the INNO-LiPA assay, 30 samples had genotype 4 (97%), and 1 sample had genotype 1e (3%). One sample showed mixed infection with type 4f and type 1. Only six samples were subtypable by INNO-LiPA, three were genotype 4c/d, and the other three were 4f, 4e, and 1e. Seven samples gave reactivity in the INNO-LiPA of lines 5, 6, 16, 17, 18, which are considered untypable by the interpretation chart but considered to be a rare HCV genotype 4 by the manufacturer. At the genotype level, there was a 97% concordance between TRUGENE sequencing and INNO-LiPA, but at the subtype level the concordance rate was 3% only. We conclude that the TRUGENE genotyping assay is a reliable test for HCV genotyping for the detection of major types and subtypes detection, while INNO-LiPA is a good test at the genotype level but unreliable for subtyping especially in the Egyptian population. This is mainly due to the high diversity of genotype 4, which is the most prevalent genotype in Egypt.

show abstract

“…Chronic hepatitis and liver cirrhosis have been documented in 70% and 20%, respectively, of those chronically infected [2,3]. Egypt has an overall HCV antibody prevalence around 15% in the general population [4][5][6][7] and genotype 4 has been identified in about 90% of HCV isolates [8][9][10][11][12]. Despite recent improvements in antiviral therapy with interferon and ribavirin, only about half of those who meet the criteria for treatment will respond to therapy.…”

Section: Introductionmentioning

confidence: 99%

Impact of past HBV exposure on virological response to combined interferon ribavirin therapy in patients with chronic HCV genotype 4

Said¹,

El-Raziky²,

Abdel-Hamid³

et al. 2011

OJIM

View full text Add to dashboard Cite

show abstract

Hepatitis C Virus Genotyping versus Serotyping in Egyptian Patients

Abstract: Type 4 HCV is the most prevalent type in Egyptian CAH patients and there is a high concordance between the results of serotyping and genotyping techniques.

Cited by 24 publications

References 9 publications

High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002

High Prevalence of Hepatitis C Virus Type 5 in Central France Evidenced by a Prospective Study from 1996 to 2002

TRUGENE sequencing versus INNO-LiPA for sub-genotyping of HCV genotype-4

Impact of past HBV exposure on virological response to combined interferon ribavirin therapy in patients with chronic HCV genotype 4

Contact Info

Product

Resources

About